The announcement was made after market hours on Friday, 20 June 2014.

Meanwhile, the BSE Sensex was down 71.98 points, or 0.29%, to 25,033.53.

On BSE, so far 31,000 shares were traded in the counter, compared with an average volume of 5,751 shares in the past one quarter.

The stock hit a high of Rs 1,245 and a low of Rs 1,130.10 so far during the day. The stock hit a 52-week high of Rs 1,285 on 4 March 2014. The stock hit a 52-week low of Rs 634 on 6 August 2013.

The stock had underperformed the market over the past one month till 20 June 2014, falling 1.02% compared with 2.99% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 0.35% as against Sensex's 15.48% rise.

The small-cap company has an equity capital of Rs 5 crore. Face value per share is Rs 2.

In March this year, AstraZeneca Pharma India's board had approved the proposal from AstraZeneca Pharmaceuticals AB, Sweden (AZP AB), the promoter of the company, to delist the equity shares of the company from Indian stock exchanges (BSE, NSE and Bangalore Stock Exchange).

AZP AB holds 75% in the Indian unit (as per shareholding pattern as on 31 March 2014).

Astrazeneca Pharma India reported net loss of Rs 2.57 crore in Q4 March 2014 as against net loss of Rs 18.58 crore in Q4 March 2013. Net sales rose 20.35% to Rs 114.15 crore in Q4 March 2014 over Q4 March 2013.

AstraZeneca Pharma India is one of the leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.